340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
Executive Summary
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.
You may also be interested in...
340B And Innovation: Study Says Hospitals Keeping Rx Payments That Could Otherwise Fuel Drug R&D
Funded in part by Arnold Ventures, the NEJM study offers more data supporting the Rx industry’s call for 340B reform, and another perspective on how the savings could be used to benefit patients.
As Pricing Scrutiny Turns To Physician-Administered Drugs, PhRMA Points To Supply Chain Culprits
Hospital receive an average of 2.5 times what they pay for drugs in reimbursement from commercial payers, a white paper released by the trade group reports. And consolidation has increased the leverage hospitals wield in payment negotiations.
340B And US Drug Pricing: Trump’s First Target Is One That Lasts
The US government program that allows safety net providers to purchase drugs at deep discounts is probably not what most American voters have in mind when they say drug pricing is a top issue. But the 340B program has been a rare area of consistent focus – and actual sustained change – in the Trump Administration.